Thermo Fisher Scientific has agreed to divest its microbiology division to private equity firm Astorg in a deal valued at approximately $1.08bn, according to a report company statement. The transaction will be funded through a combination of cash proceeds and a $50m seller note.
The transaction was made via Astorg VIII and represents the funds’ tenth investment to date.
The business being sold focuses on antimicrobial susceptibility testing and culture media, with applications spanning clinical...
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.
Alternative Investment News